Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE.
Brown JR, Eichhorst B, Lamanna N, O'Brien SM MD, Tam CS, Qiu L, Jurczak W, Zhou K, Šimkovič M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T Prof, Osterborg A, Yimer HA, Wang MY, Salmi T, Wang L, Li J, Wu K, Cohen AC, Shadman M.
Brown JR, et al.
Blood. 2024 Sep 24:blood.2024024667. doi: 10.1182/blood.2024024667. Online ahead of print.
Blood. 2024.
PMID: 39316666
ALPINE (NCT03734016) established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL); here we present data from the final comparative analysis with extended fol …
ALPINE (NCT03734016) established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leu …